Literature DB >> 21903653

The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient.

P Friederich, H Pfizenmayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21903653     DOI： 10.1093/bja/aer278

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


× No keyword cloud information.
  3 in total

Review 1.  Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.

Authors:  Wei Wu; Michael C Sanguinetti
Journal:  Card Electrophysiol Clin       Date:  2016-03-18

2.  Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients.

Authors:  Alain Rudiger; Alexander Breitenstein; Mattia Arrigo; Sacha P Salzberg; Dominique Bettex
Journal:  Crit Care Res Pract       Date:  2014-05-12

Review 3.  The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?

Authors:  A John Camm
Journal:  Curr Cardiol Rev       Date:  2014-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.